The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281
Abstract
Purpose: Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain. Patients and Methods: Two hundred forty-nine patients with advanced carcinoid tumors were randomized to either doxorubicin with fluorouracil (FU/DOX) or streptozocin with fluorouracil (FU/STZ). Patients crossed over to the dacarbazine (DTIC) treatment after disease progression following first-line treatment (either FU/DOX or FU/STZ), and 73 patients were assigned to one of these three treatments based on their previous treatment or on abnormal baseline cardiac or renal function. Results: In the randomized group, there was no difference between FU/DOX and FU/STZ in response rates (15.9% v 16%) and progression-free survival (4.5 v 5.3 months). FU/STZ (24.3 months) was superior to FU/DOX (15.7 months; P = .0267) in median survival. The response rate of crossover DTIC treatment was 8.2%, with a median survival of 11.9 months. Hematologic toxicities were the major treatment-related toxicities for both FU/DOX and FU/STZ, and mild to moderate renal toxicity was reported in 40 (34.8%) of 115 patients in the FU/STZ arm. Conclusion: Response to all three treatment regimens were modest. FU/STZ improved survival compared with the doxorubicin-based regimen, suggesting that the combination should be considered to be an active regimen of therapy when chemotherapy is judged to be an option for selected patients with carcinoid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Carcinoid TumorsAn analysis of 2837 cases
Godwin, J. D. (1975) · Cancer · doi:10.1002/1097-0142(197508)36:2<560::aid-cncr2820360235>3.0.co;2-4 · Cited by 1,106
Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., & ITMO Association (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4 · Cited by 296
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
Moertel, C. G., & Hanley, J. A. (1979) · PubMed · Cited by 277
Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.
Engstrom, P. F., Lavin, P. T., Moertel, C. G., Folsch, E., & Douglass, H. O. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1255 · Cited by 270
Janson, E. T., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083916 · Cited by 204
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors
Bajetta, E., Rimassa, L., Carnaghi, C., Seregni, E., Ferrari, L., Bartolomeo, M. D., Regalia, E., Cassata, A., Procopio, G., & Mariani, L. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980715)83:2<372::aid-cncr23>3.0.co;2-p · Cited by 165
Antiproliferative Effect of Somatostatin and Analogs
Bousquet, C., Puente, E., Buscail, L., Vaysse, N., & Susini, C. (2001) · Chemotherapy · doi:10.1159/000049159 · Cited by 116
A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
Ansell, S. M., Pitot, H. C., Burch, P. A., Kvols, L. K., Mahoney, M. R., & Rubin, J. (2001) · Cancer · doi:10.1002/1097-0142(20010415)91:8<1543::aid-cncr1163>3.0.co;2-n · Cited by 107
Bukowski, R. M., Johnson, K. G., Peterson, R. F., Stephens, R. L., Rivkin, S. E., Neilan, B. A., & Costanzi, J. H. (1987) · Cancer · doi:10.1002/1097-0142(19871215)60:12<2891::aid-cncr2820601207>3.0.co;2-6 · Cited by 98
Garland, J., Buscombe, J. R., Bouvier, C., Bouloux, P. M., Chapman, M. H., Chow, A. C., Reynolds, N., & Caplin, M. E. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01420.x · Cited by 83
Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine.
Ga, V. H., Rubin, J., & Cg, M. (1983) · PubMed · Cited by 53
Neijt, J. P., Lacave, A. J., Splinter, T. A. W., Taal, B. G., Veenhof, C. H. N., Sahmoud, T., & Lips, C. J. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.21 · Cited by 24
Cited by
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Metadata
- Authors
- Sun, W., Lipsitz, S., Catalano, P., Mailliard, J. A., & Haller, D. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 4897-4904
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107276199
- Cited by
- 357
- References
- 14
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.